This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
by Ekta Bagri
Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.
LQDANegative Net Change UTHRNegative Net Change INSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
by Zacks Equity Research
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
by Zacks Equity Research
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
AMGNPositive Net Change RGENPositive Net Change ANIKNegative Net Change PGENPositive Net Change
biotechs
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
by Ahan Chakraborty
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
by Zacks Equity Research
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
CLDXPositive Net Change KODPositive Net Change PCVXNegative Net Change RAPPNegative Net Change
biotechnology biotechs
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
by Zacks Equity Research
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
INSMNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechs medical
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
by Zacks Equity Research
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
ALKSPositive Net Change RGENPositive Net Change PGENPositive Net Change
biotechs
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
by Zacks Equity Research
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.
NVONegative Net Change LLYNegative Net Change ALDXPositive Net Change ACIUNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
by Ahan Chakraborty
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
CLDXPositive Net Change KODPositive Net Change PCVXNegative Net Change RAPPNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
by Sundeep Ganoria
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
MRNAPositive Net Change SNYNegative Net Change PFENo Net Change MRKPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines